DarioHealth stock falls 5.73 percent despite 62 percent Q2 margin

Published on 10/05/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DarioHealth stock was trading at USD 6.09 on October 5, 2026, while the company reported a 62 percent Q2 gross margin. Contracted ARR reached USD 13.1 million, and a New Jersey plan could add 1.5 million covered lives.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth (ISIN US23725P3082) was trading at USD 6.09 on Nasdaq on October 5, 2026, down 5.73 percent from the previous close. The decline puts the digital health company below its 52-week high of USD 16.55, while its 52-week low stands at USD 5.84. The latest market move contrasts with a business update centered on higher margins and future recurring revenue.

Q2 margin reaches 62 percent

DarioHealth reported USD 5.2 million in second-quarter 2026 revenue, compared with USD 5.6 million in the first quarter and USD 5.4 million in the second quarter of 2025, according to Yahoo Finance on August 11, 2026. Gross margin rose to 62 percent from 57 percent in the first quarter and 55 percent a year earlier.

The earnings call also showed the tension in the transition: Dario posted a USD 7.9 million net loss for the quarter, compared with USD 13.0 million a year earlier. That represented a 39 percent improvement, while management said the shift away from pharmaceutical services reduced near-term revenue but increased the share of recurring B2B2C activity, as Yahoo Finance reported.

Contracted ARR targets 2027

Dario ended the second quarter with USD 13.1 million in contracted and late-stage annual recurring revenue, and more than 80 percent of that total was tied to multi-condition offerings. The company says implementation and enrollment cycles typically take four to five quarters, making conversion timing as important as the headline contract value.

That timing was illustrated by a September 17, 2026 agreement with a New Jersey health plan representing 1.5 million covered lives. The program is expected to launch and begin generating revenue in the first quarter of 2027 through Dario's partnership with Amwell, according to Yahoo Finance.

Losses remain the key counterweight

For investors, the central tradeoff is visible in the numbers: a 62 percent gross margin and USD 13.1 million of contracted ARR sit alongside a USD 7.9 million quarterly net loss. Dario's management expects signed accounts to contribute more meaningfully from the second half of 2026, with the largest contribution expected in 2027.

DRIO stock trades near its yearly low

DRIO was last at USD 6.09 on Nasdaq on October 5, 2026 at 2:43 p.m. ET, with a market capitalization of USD 44.5 million and volume of 16,095 shares. The price was USD 10.46 below the 52-week high of USD 16.55, leaving the current quotation much closer to the yearly low than the yearly peak.